title: [AB0 incompatible kidney transplantation - first experiences].
abstract: Living donor AB0 incompatible kidney transplantation represents a new tool how to improve the access to transplantation. Majority of European protocols are based on desensitization with rituximab, triple drug immunosuppression, intravenous immunoglobulins and specific immunoads option (IA) which eliminates isohaemaglutinins. AB0i kidney transplant program was initiated in our centre in 2011 and 21 patients have received grafts from incompatible donors until recently. Highest accepted isohaemaglutinins titers before rituximab were 1 : 64 and corresponding pretransplant immunoadsorption procedures varied from 2 to 9. In 5 patients 1-2 IA procedures were performed also after transplantation. With the advent of paired exchange program the AB0i transplantation is offered to patients with unsuccessful matching run or with aim to improve HLA match between donor and recipient. The main complications were postoperative bleeding and urinary tract infections in patients at risk. Majority of protocol biopsies exhibited positivity of C4d staining. Neither graft loss nor patient death were noticed.
authors.forename: Ondřej
authors.initials: O
authors.lastname: Viklický
authors.forename: Alena
authors.initials: A
authors.lastname: Paříková
authors.forename: Janka
authors.initials: J
authors.lastname: Slatinská
authors.forename: Vladimír
authors.initials: V
authors.lastname: Hanzal
authors.forename: Libuše
authors.initials: L
authors.lastname: Pagáčová
authors.forename: Eva
authors.initials: E
authors.lastname: Honsová
authors.forename: Eva
authors.initials: E
authors.lastname: Kieslichová
authors.forename: Libor
authors.initials: L
authors.lastname: Janoušek
authors.forename: Jiří
authors.initials: J
authors.lastname: Froněk
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D001787:Blood Group Incompatibility; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016030:Kidney Transplantation; D019520:Living Donors; D008297:Male; D000069283:Rituximab / Q000627:therapeutic use*; D014181:Transplantation Immunology
chemical_list: D000017:ABO Blood-Group System; D007155:Immunologic Factors; D000069283:Rituximab